Stay updated on Subcutaneous Lirentelimab in Atopic Dermatitis Clinical Trial
Sign up to get notified when there's something new on the Subcutaneous Lirentelimab in Atopic Dermatitis Clinical Trial page.

Latest updates to the Subcutaneous Lirentelimab in Atopic Dermatitis Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page shows a revision bump from v3.4.1 to v3.4.2 with no changes to study content, eligibility criteria, endpoints, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check18 days agoChange DetectedA minor revision update from v3.4.0 to v3.4.1; core study details remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check33 days agoChange DetectedMinor UI and text updates: glossary show/hide controls were added, and footer text was updated to reflect capitalization and a new revision tag (v3.4.0).SummaryDifference0.2%

- Check40 days agoChange DetectedRevision label updated from v3.3.3 to v3.3.4. No substantive study information or functionality appears to be affected.SummaryDifference0.0%

- Check62 days agoChange DetectedAdded a comprehensive Locations section listing study sites across multiple states (Alabama, Arizona, California, Colorado, District of Columbia, Florida, Kentucky, Louisiana, Maryland, Massachusetts, Minnesota, Montana, Nebraska, Nevada, New York, Ohio, Oklahoma, Oregon, Pennsylvania, Texas, Utah, Washington) and included the Revision: v3.3.3 label.SummaryDifference2%

- Check91 days agoChange DetectedThe page revision history shows an update from v3.2.0 to v3.3.2, a minor metadata change that does not affect study content, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Subcutaneous Lirentelimab in Atopic Dermatitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Subcutaneous Lirentelimab in Atopic Dermatitis Clinical Trial page.